Skip to content
DataLookout
Start free
Menu

NCT05397431

A Survey of Lanadelumab in Participants With Hereditary Angioedema

StatusCompleted
PhaseNot specified
SponsorTakeda
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revised Show 4 more changesShow less
    • Trial completed
    • Enrollment target: 155 to 157
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study site revised
  2. Primary and study completion pushed from Jun 25, 2026 to Oct 27, 2026v8
  3. Primary and study completion pushed from Jan 31, 2026 to Jun 25, 2026
    • Trial status: Completed to Active, Not Recruiting
    v7
  4. Trial status: Recruiting to Completed
    • Enrollment target: estimated 100 to confirmed 155
    • Site details revised
    v6
  5. Primary and study completion dates: Aug 31, 2026 to Jan 31, 2026
    • Site details revised
    v5
Show 2 earlier versionsHide 2 earlier versions
  1. Study Status, Eligibilityv4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Who Experienced At Least One Treatment-Emergent Adverse Event (TEAE)
Timeframe: 12 Months

Secondary (2)

Number of Angioedema Attacks
Angioedema Quality of life (AE-QoL) Questionnaire

Arms and interventions

Lanadelumab

Participants will receive 300 milligram (mg) of Lanadelumab Subcutaneous (SC) injection once every 2 weeks.

Drugs: Lanadelumab

Sites

1 site in 1 country

  • Takeda Selected SiteTokyo, Tokyo, Japan